This patent broadly covers the use of the URG101 product in the treatment of painful bladder syndrome or interstitial cystitis (PBS/IC). The term of the patent extends into 2025.
Urigen has also announced positive results from a Phase II study of URG101. The study was a multi-center, double-blind, placebo-controlled, crossover trial.
Findings from the study included, primary endpoint – improvement in average daytime pain (p=0.03), secondary endpoints – improvement in daytime urgency (p=0.03) and total symptom score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by Poris (p=0.01).
William Garner, president and CEO of Urigen, said: “We will continue to execute our intellectual property strategy to strengthen our proprietary position in the field of PBS/IC.”